LUPAGEN


Associated tags: Immunotherapy, Gene editing, Inc., Hospitals, Collection, Vaccine, Autoimmunity, Rare, R, Transfusion medicine, Cell, Cancer, Blood, Patient, Kabi, Genetics, Gene, Fresenius (company), Oncology, General Health, Health, Other Health, Biotechnology

Locations: TX

Fresenius Kabi and Lupagen Enter into Strategic Development and Supply Agreement to Bring Cell and Gene Therapies to the Bedside

Retrieved on: 
Thursday, August 24, 2023
Hospitals, Genetics, Fitness & Nutrition, Stem Cells, Biotechnology, Other Health, Health, General Health, Oncology, Fresenius (company), Gene, Multimedia, Kabi, Collection, Patient, Blood, Cancer, Cell, Transfusion medicine, R, Rare, Autoimmunity, Vaccine, Medical device

Fresenius Kabi and Lupagen Inc. announced today the companies have entered into a development and supply agreement for technologies designed to bring the delivery of cell and gene therapies to the bedside.

Key Points: 
  • Fresenius Kabi and Lupagen Inc. announced today the companies have entered into a development and supply agreement for technologies designed to bring the delivery of cell and gene therapies to the bedside.
  • View the full release here: https://www.businesswire.com/news/home/20230824736387/en/
    Cell and gene therapies have shown great promise for a wide array of conditions including cancers and hematologic, autoimmune, and rare diseases.
  • Under the terms of the agreement, Fresenius Kabi will provide their expertise in apheresis collection and automated cell processing equipment to advance Lupagen’s Extracorporeal Cell and Gene Therapy Delivery System, which focuses on simplifying and reducing costs for cell and gene therapy through a bedside procedure.
  • “Lupagen’s mission is to make cell and gene therapy as common and widely accessible as standard blood transfusion or dialysis procedures.